Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity

• Hauptverfasser: Pushpendra Goswami (VerfasserIn), Esther N. Oliva (VerfasserIn), Tatyana Ionova (VerfasserIn), Roger Else (VerfasserIn), Jonathan Kell (VerfasserIn), Adele K. Fielding (VerfasserIn), Daniel M. Jennings (VerfasserIn), Marina Karakantza (VerfasserIn), Saad Al-Ismail (VerfasserIn), Graham P. Collins (VerfasserIn), Stewart McConnell (VerfasserIn), Catherine Langton (VerfasserIn), Sam Salek (VerfasserIn)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2020-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

BackgroundThe quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patients...